Radius Health, Inc. (RDUS)
USD 29.06
(-0.03%)
USD 29.06
(-0.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -25.79 Million USD | -115.28% |
| 2022 | 168.8 Million USD | 2.23% |
| 2021 | 165.11 Million USD | 4083.4% |
| 2020 | -4.14 Million USD | 96.88% |
| 2019 | -132.99 Million USD | 39.91% |
| 2018 | -221.33 Million USD | 12.94% |
| 2017 | -254.23 Million USD | -39.08% |
| 2016 | -182.8 Million USD | -80.06% |
| 2015 | -101.52 Million USD | -62.5% |
| 2014 | -62.47 Million USD | -2.95% |
| 2013 | -60.69 Million USD | 12.21% |
| 2012 | -69.12 Million USD | -62.75% |
| 2011 | -42.47 Million USD | -90695.61% |
| 2010 | -46.78 Thousand USD | -46.23% |
| 2009 | -31.99 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -25.79 Million USD | -115.28% |
| 2023 Q1 | 4.35 Million USD | 124.47% |
| 2023 Q2 | 13.46 Million USD | 209.21% |
| 2023 Q3 | -25.81 Million USD | -291.8% |
| 2023 Q4 | -17.96 Million USD | 30.42% |
| 2022 Q4 | -17.78 Million USD | -271.83% |
| 2022 Q1 | -23.09 Million USD | -16.92% |
| 2022 Q2 | -17.59 Million USD | 23.83% |
| 2022 FY | 168.8 Million USD | 2.23% |
| 2022 Q3 | 10.35 Million USD | 158.84% |
| 2021 Q2 | -16.81 Million USD | -6.74% |
| 2021 Q3 | -22.03 Million USD | -31.07% |
| 2021 Q4 | -19.75 Million USD | 10.34% |
| 2021 Q1 | -15.74 Million USD | -73545.08% |
| 2021 FY | 165.11 Million USD | 4083.4% |
| 2020 Q1 | -37.65 Million USD | -52.35% |
| 2020 Q3 | -6.28 Million USD | 85.67% |
| 2020 Q4 | -21.38 Thousand USD | 99.66% |
| 2020 FY | -4.14 Million USD | 96.88% |
| 2020 Q2 | -43.88 Million USD | -16.53% |
| 2019 Q1 | -42.76 Million USD | -4.04% |
| 2019 Q2 | -35.47 Million USD | 17.04% |
| 2019 Q4 | -24.71 Million USD | 17.74% |
| 2019 Q3 | -30.04 Million USD | 15.31% |
| 2019 FY | -132.99 Million USD | 39.91% |
| 2018 Q1 | -61.55 Million USD | 13.32% |
| 2018 FY | -221.33 Million USD | 12.94% |
| 2018 Q4 | -41.09 Million USD | 17.48% |
| 2018 Q3 | -49.8 Million USD | 27.7% |
| 2018 Q2 | -68.88 Million USD | -11.9% |
| 2017 FY | -254.23 Million USD | -39.08% |
| 2017 Q4 | -71.01 Million USD | -22.78% |
| 2017 Q3 | -57.84 Million USD | 15.48% |
| 2017 Q2 | -68.43 Million USD | -20.2% |
| 2017 Q1 | -56.93 Million USD | -8.0% |
| 2016 Q4 | -52.72 Million USD | -14.15% |
| 2016 FY | -182.8 Million USD | -80.06% |
| 2016 Q1 | -40.46 Million USD | -21.73% |
| 2016 Q3 | -46.18 Million USD | -6.33% |
| 2016 Q2 | -43.43 Million USD | -7.34% |
| 2015 FY | -101.52 Million USD | -62.5% |
| 2015 Q2 | -22.96 Million USD | -34.64% |
| 2015 Q1 | -17.05 Million USD | 5.04% |
| 2015 Q3 | -28.26 Million USD | -23.07% |
| 2015 Q4 | -33.24 Million USD | -17.61% |
| 2014 Q1 | -14.48 Million USD | -15.62% |
| 2014 FY | -62.47 Million USD | -2.95% |
| 2014 Q4 | -17.96 Million USD | -3.11% |
| 2014 Q3 | -17.42 Million USD | -38.16% |
| 2014 Q2 | -12.6 Million USD | 12.97% |
| 2013 Q2 | -19.51 Million USD | -134.94% |
| 2013 Q3 | -20.34 Million USD | -4.25% |
| 2013 Q4 | -12.53 Million USD | 38.4% |
| 2013 FY | -60.69 Million USD | 12.21% |
| 2013 Q1 | -8.3 Million USD | 60.0% |
| 2012 Q4 | -20.76 Million USD | -18.45% |
| 2012 Q1 | -12.87 Million USD | -23.12% |
| 2012 Q2 | -17.96 Million USD | -39.54% |
| 2012 Q3 | -17.53 Million USD | 2.4% |
| 2012 FY | -69.12 Million USD | -62.75% |
| 2011 Q4 | -10.45 Million USD | -10.94% |
| 2011 Q1 | -10.14 Thousand USD | 59.87% |
| 2011 Q2 | -17.58 Million USD | -173300.37% |
| 2011 Q3 | -9.42 Million USD | 46.42% |
| 2011 FY | -42.47 Million USD | -90695.61% |
| 2010 Q3 | -6038.00 USD | -4.92% |
| 2010 Q2 | -5755.00 USD | 40.74% |
| 2010 FY | -46.78 Thousand USD | -46.23% |
| 2010 Q1 | -9711.00 USD | -93.72% |
| 2010 Q4 | -25.27 Thousand USD | -318.65% |
| 2009 FY | -31.99 Thousand USD | 0.0% |
| 2009 Q4 | -5013.00 USD | 20.73% |
| 2009 Q3 | -6324.00 USD | 4.51% |
| 2009 Q2 | -6623.00 USD | 52.8% |
| 2009 Q1 | -14.03 Thousand USD | 0.0% |
| 2008 Q3 | -7044.00 USD | 0.0% |
| 2008 Q4 | - USD | 100.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 153.558% |
| Embecta Corp. | 70.4 Million USD | 136.635% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 237.34% |
| Dynavax Technologies Corporation | -6.38 Million USD | -303.678% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 87.674% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 161.473% |
| PainReform Ltd. | -9.34 Million USD | -176.017% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -227.713% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -472.365% |
| SCYNEXIS, Inc. | 67.04 Million USD | 138.47% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -732.362% |
| Cosmos Health Inc. | -18.54 Million USD | -39.09% |
| Journey Medical Corporation | -3.85 Million USD | -569.375% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -472.365% |
| Safety Shot Inc | -15.08 Million USD | -70.993% |
| Alpha Teknova, Inc. | -36.78 Million USD | 29.878% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 81.535% |
| Bright Green Corporation | -13.12 Million USD | -96.463% |
| Procaps Group, S.A. | 42.54 Million USD | 160.628% |
| Theratechnologies Inc. | -23.95 Million USD | -7.655% |
| Harrow Health, Inc. | -24.41 Million USD | -5.653% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -433.423% |
| Biofrontera Inc. | -20.13 Million USD | -28.116% |
| DURECT Corporation | -27.62 Million USD | 6.636% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 2059.802% |
| Cronos Group Inc. | -73.96 Million USD | 65.13% |
| OptiNose, Inc. | -35.48 Million USD | 27.314% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 97.427% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 38.882% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 207.84% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 621.557% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 16420.009% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -310.729% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -318.477% |
| ProPhase Labs, Inc. | -16.78 Million USD | -53.683% |
| Phibro Animal Health Corporation | 2.41 Million USD | 1167.508% |
| Procaps Group S.A. | 42.54 Million USD | 160.628% |
| Alvotech | -551.73 Million USD | 95.325% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -150.934% |
| Viatris Inc. | 54.7 Million USD | 147.15% |
| Rockwell Medical, Inc. | -8.43 Million USD | -205.617% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -62.781% |
| SIGA Technologies, Inc. | 68.06 Million USD | 137.89% |
| Tilray Brands, Inc. | -244.98 Million USD | 89.472% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 314.692% |
| Shineco, Inc. | -22.44 Million USD | -14.887% |
| PetIQ, Inc. | 2.13 Million USD | 1310.277% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -499.535% |
| Incannex Healthcare Limited | -18.45 Million USD | -39.72% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 110.329% |
| Alimera Sciences, Inc. | -20.13 Million USD | -28.109% |
| Silver Spike Investment Corp. | 7.34 Million USD | 451.371% |
| Assertio Holdings, Inc. | -331.94 Million USD | 92.23% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -291.204% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -215.943% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -44.092% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -28.587% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 83.908% |
| Hempacco Co., Inc. | -13.12 Million USD | -96.487% |
| Talphera, Inc. | -18.39 Million USD | -40.191% |
| Alvotech | -551.73 Million USD | 95.325% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 172.361% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 107.895% |
| Currenc Group, Inc. | -15.3 Million USD | -68.496% |
| Kamada Ltd. | 8.28 Million USD | 411.335% |
| Indivior PLC | 2 Million USD | 1389.55% |
| Evoke Pharma, Inc. | -7.79 Million USD | -230.981% |
| Flora Growth Corp. | -57.03 Million USD | 54.781% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -28.587% |
| Evolus, Inc. | -61.68 Million USD | 58.189% |
| HUTCHMED (China) Limited | 100.78 Million USD | 125.591% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 118.751% |
| Akanda Corp. | -32.27 Million USD | 20.09% |